The HDAC inhibitors are mostly non-isoform selective and with recent advances in drug discovery, isoform specific and dual capability HDAC inhibitors have been extensively developed for cancer treatment (Peng et al., 2020). This evidence concerns the gene HDAC9 and cancer.